RETHINK-ALZ
Simufilam 100 mg for Mild to Moderate Alzheimer’s Disease
Alzheimer’s Study
PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects
PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects Inclusion Criteria Age 55-90 years Have a reliable study partner, an identified adult who has sufficient contact to knowledgeably report on the subject’s daily cognition, function, behavior, safety, compliance and adherence. Have a clinical diagnosis of mild-to-moderate AD Visual and …
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3)
The Alzheimer’s Disease Neuroimaging Initiative (also known as ADNI) is a historic study of brain aging looking to help change the future for this disease.